Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and…
<!-- Name:DistributionId Value:8843470 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Dupixent
Sanofi, Regeneron shares pop more than 6% after data shows asthma drug Dupixent may…
A logo on the Sanofi exhibition space at the Viva Technology conference dedicated to innovation and startups at Porte de Versailles exhibition center in Paris, France June 15, 2022.Benoit…
Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD…
<!-- Name:DistributionId Value:8793979 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted…
<!-- Name:DistributionId Value:8791865 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in…
<!-- Name:DistributionId Value:8790647 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Dupixent® (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria…
<!-- Name:DistributionId Value:8782894 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted…
<!-- Name:DistributionId Value:8738545 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Dupixent® (dupilumab) Recommended for Expanded EU Approval by the CHMP to Treat…
<!-- Name:DistributionId Value:8737493 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Data on Dupixent in Eosinophilic Esophagitis Now Published
Dupilumab (Dupixent) was superior to placebo in the phase III trial underpinning its…
FDA Approves Dupixent for Prurigo Nodularis
Physician’s Briefing Staff
FRIDAY, Sept. 30, 2022 (HealthDay News) -- The U.S. Food and Drug Administration approved Dupixent (dupilumab) as the first…